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Introduction: It is well known that etomidate may cause adrenal insufficiency. However, the clinical relevance of
adrenal suppression after a single dose of etomidate remains vague. The aim of this study was to investigate the
association between the administration of a single dose of etomidate or an alternative induction regime ahead of
major cardiac surgery and clinical outcome parameters associated with adrenal suppression and onset of sepsis.
Methods: The anesthesia and intensive care unit (ICU) records from patients undergoing cardiac surgery over five
consecutive years (2008 to 2012) were retrospectively analyzed. The focus of the analysis was on clinical parameters
like mortality, ventilation hours, renal failure, and sepsis-linked serum parameters. Multivariate analysis and Cox
regression were applied to derive the results.
Results: In total, 3,054 patient records were analyzed. A group of 1,775 (58%) patients received a single dose of
etomidate; 1,279 (42%) patients did not receive etomidate at any time. There was no difference in distribution of
age, American Society of Anesthesiologists physical score, duration of surgery, and Acute Physiology and Chronic
Health Evaluation II score. Postoperative data showed no significant differences between the two groups in regard
to mortality (6.8% versus 6.4%), mean of mechanical ventilation hours (21.2 versus 19.7), days in the ICU (2.6 versus
2.5), hospital days (18.7 versus 17.4), sepsis-associated parameters, Sequential Organ Failure Assessment score, and
incidence of renal failure. Administration of etomidate showed no significant influence (P = 0.6) on hospital mortality
in the multivariate Cox analysis.
Conclusions: This study found no evidence for differences in key clinical outcome parameters based on anesthesia
induction with or without administration of a single dose of etomidate. In consequence, etomidate might remain
an acceptable option for single-dose anesthesia induction.Introduction
Etomidate is considered an almost ideal induction agent be-
cause of the rapid onset and the predictable short duration
of action in combination with minimal implications for the
cardiovascular and pulmonary system [1]. These effects and
benefits are even more important in high-risk cardiac sur-
gery patients. However, soon after licensing of etomidate
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unless otherwise stated.mortality in intensive care patients resulted in recommen-
dations to stop long-term use [2-4]. Even a single dose of
etomidate inhibits transiently adrenal mitochondrial 11-β-
hydroxylase activity with consecutive adrenal suppression
[5,6]. Ever since, intensive care, emergency, and anesthesia
communities have been discussing the use of even a single
dose of etomidate controversially. Various studies and
meta-analyses found either an increased [7-10] or an equal
[11-17] risk of mortality and risk variables after administra-
tion of etomidate in critically ill patients with sepsis. In
trauma patients, an increased susceptibility to pneumonia
is attributed to etomidate [18].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ahead of cardiac surgery. In this context, smaller studies
showed that etomidate is associated with increased
vasopressor requirements [19]. Other authors report a
relative adrenal insufficiency and deny an increase of
vasopressor requirements [20]. In a retrospective ana-
lysis of 3,127 patients receiving etomidate or propofol,
Wagner and colleagues [21] showed no increase in se-
vere hypotension, in-hospital mortality, duration of hos-
pital stay, intensive care unit (ICU) stay, and duration of
mechanical ventilation. Further evidence for postopera-
tive systemic inflammatory response syndrome (SIRS)
due to adrenal insufficiency is of particular relevance for
patients after on-pump cardiac surgery. It is well known
that on-pump cardiac surgery per se is a risk factor for
postoperative SIRS and infections [22]. The objective of
our study was to determine differences in key clinical
outcome parameters following anesthesia induction with
administration of etomidate or an alternative induction
regime. Analyzed parameters for clinical outcome were
sepsis-associated serum parameters, duration of mech-
anical ventilation, morbidity scores, renal failure, length
of ICU stay, and ICU and hospital mortality.
Materials and methods
Ahead of this study, the local ethics committee (Ethics
Committee of Friedrich-Alexander University Erlangen-
Nürnberg) confirmed that no further patients’ consent and
institutional ethical approval were required. This decision
was based on the retrospective, descriptive, and anonymous
study design and the fully closed patient files.
All anesthesia and ICU records from adult patients
undergoing general anesthesia for major on-pump cardiac
surgery at the university hospital in five consecutive years
(January 2008 to December 2012) were analyzed retro-
spectively. The filed anesthesia records were retrieved from
an electronic patient data management system (PDMS)
(NarkoData Imeso, Hüttenberg, Germany) including an
unambiguous and unique case identifier number (UCIN)
(Figure 1). The UCIN is a pre-existing code of 13 digits to
uniquely identify an individual case and is used to collect
all available data from different PDMSs of a specific case to
create the invoice for health insurance companies. Anon-
ymized data were transferred to an MS Office 2010 Access®
database (Microsoft Corporation, Redmond, WA, USA) in-
cluding age, height, weight, Mallampati score, Acute Physi-
ology and Chronic Health Evaluation II (APACHE II) score
[23], Cormack and Lehane (CML) classification, priority of
surgery, anesthesia drugs, and aortic clamping, bypass, and
operation times. The postoperative ICU patient data were
retrieved from the PDMS (ICM Dräger, Lübeck, Germany)
and matched with the anesthesia data by using the UCIN.
These data include laboratory parameters, duration of
mechanical ventilation, length of ICU stay, ICU mortality,and Sequential Organ Failure Assessment (SOFA) score
[24,25]. The ICM data are redundantly stored in the hos-
pital PDMSs (Lauris and Soarian; Siemens, Erlangen,
Germany) to facilitate access also from the normal care
wards to these data (laboratory test results). Additional data
which are available only in the hospital PDMSs (Lauris® and
Soarian®) were also transferred and matched with the study
database by using the UCIN. The data abstractors were
qualified and experienced in the field of medical data man-
agement. For every PDMS, a single abstractor worked inde-
pendently and fully blinded to the purpose of the study.
The complete data of an observed case could be seen by
the investigator group only after the matching in the study
database. After the matching with the UCIN, the date of
birth of the patient in the two datasets was compared to get
a secondary check for the correct match of the datasets. If
the date of birth had not been identical in the datasets, the
study database would have alerted the investigator to a data
mismatch (plausibility control). However, such a mismatch
was not observed in any of the cases of this study.
Patients who reached the operation theatre already
intubated and sedated were excluded from the analysis,
as the anesthetic drugs used for intubation could not be
verified in these cases. Patients with an ICU admission
ahead of major cardiac surgery were also excluded from
the analysis as their morbidity and mortality odds ahead
of cardiac surgery may differ significantly from those of
the other patients. For the same reason, cases with re-
petitive major cardiac surgery and off-pump coronary ar-
tery bypass grafting were excluded.
The cardiac surgery department contributing to this
study provides a full spectrum of cardiac surgery for pa-
tients of every age, including heart transplantation and de-
vice surgery. The university hospital at Erlangen is a
tertiary center with approximately 1,400 beds and pro-
vides about 900 on-pump cardiac surgery interventions
per year, including around 250 interventions in pediatric
cardiac surgery. In the cardiac surgery department, anes-
thetists have at least three years of professional experience
and are under close supervision of senior physicians.
Preoperative evaluation, induction, and maintenance of
anesthesia as well as postoperative ICU treatment are per-
formed in accordance with standard operating procedures
(SOPs). The SOP for preoperative evaluation includes the
documentation of the four-scale Mallampati test result
[26]. Documentation of physical health status in accord-
ance with the American Society of Anesthesiologists (ASA)
was mandatory.
SOPs for anesthesia induction and maintenance demand
a consistent approach, including arterial catheterization
with local anesthesia, intravenous application of an opioid,
a hypnotic drug, and a neuromuscular blocking agent.
However, every anesthesiologist was free to vary the
anesthetic drug regime for induction and maintenance.
Etomidate in patients undergoing cardiac surgery
Anesthesia records from patients undergoing 
major on pump cardiac surgery. n=3212
Cases who received endotracheal intubation 
ahead of major on pump cardiac surgery.
n=3054
Dropout of cases with minor 
interventions like cardioversion,
pacemaker implants, sternal 
wounds and off pump cardiac 
surgery.
Dropout of cases who were already 
intubated and were transferred 
from ICU ahead of major on pump 
cardiac surgery
All anesthesia records from patients of the 
cardiac surgery department from 2008 to 2012
who were older than 18 years at the 
intervention. Narko Data© including unique 
case identifier number (UCIN)     n= 5335
Further statistical processing including:
Study database (MS 
Access©) with unique case 
identifier number (UCIN)
3054 anesthesia records 
with unique case identifier 
number




Hospital PDMS Data 
warehouses Soarian©, 
Lauris©: serum test results, 
hospital stay, and hospital 
mortality
data transfer
UCIN transfer UCIN transfer
Figure 1 Flow chart showing the case selection and data collection of the study. ICU, intensive care unit; PDMS, patient data management
system.
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used hypnotic drug in this analysis. Alternatively, a
combination of 1.5 to 2.0 mg/kg esketamine and 0.5 to
2 mg/kg propofol was administered for anesthesia induc-
tion. Cis-atracurium (0.15 to 0.2 mg/kg) was administered
as standard neuromuscular blocking agent. In the case of
a rapid sequence induction (RSI), 0.6 to 0.9 mg/kg rocuro-
nium was given. The direct laryngeal view was graded in
accordance with the four-scale CML classification [27].
Anesthesia was maintained with either continuous injec-
tion of propofol or inhalative application of sevoflurane
which was also administered, in parts, in the pump circuit
during cardiopulmonary bypass time. Continuous infusionof 0.4 to 0.8 μg/kg per hour sufentanil was the standard
analgesic regime. All patients received continuous infusion
of propofol at the end of surgery for transfer to the ICU
and ongoing ICU sedation. Antimicrobial prophylaxis was
performed by administration of a cephalosporine after
the anesthesia induction and a repetitive dose after car-
diopulmonary bypass. The antimicrobial regime remained
unchanged during the study period. Admission SOP in
the ICU for cardiac surgery patients includes hemogram
and serum test of myocardial necrosis indicators like gen-
eral creatinkinasis (CK), specific myocardial creatinkinasis
(CK-MB), and troponin I (TROP) as well as inflammatory
parameters like C-reactive protein (CRP). Procalcitonine







Number of patients 1,279 1,775
Sex
Female 340 (27%) 554 (31%) 0.006
Male 939 (73%) 1,221 (69%)
Age, years 67.9 ± 0.3 67.8 ± 0.2 0.600
Body mass index, kg/m2 28.2 ± 0.2 (24.8/30.7) 25.5 ± 0.2 0.994
ASA score
1 3 (0.2%) 2 (0.1%) 0.413
2 31 (2%) 59 (3%) 0.147
3 1,143 (89%) 1,548 (87%) 0.069
4 101 (8%) 163 (9%) 0.212
5 1 (0.1%) 3 (0.2%) 0.494
APACHE II score
17.0 ± 0.2 16.7 ± 0.1 0.151
Missing 73 (5.7%) 101 (5.7%)
Mallampati
1 142 (11%) 246 (14%) 0.024
2 884 (69%) 1,139 (64%) 0.004
3 168 (13%) 307 (17%) 0.002
4 15 (1%) 16 (1%) 0.460
Missing 70 (6%) 67 (4%) 0.025
Pre-operative hemoglobin
g/dL 13,1 ± 0.6 13.0 ± 0.5 0.899
Missing 217 (17%) 337 (19%)
Pre-operative creatinine
mg/dL 1.15 ± 0.2 1.15 ± 0.2 0.520
Missing 385 (30%) 365 (21%)
Pre-operative creatinine
kinase
U/L 119.1 ± 5.5 125.2 ± 5.7 0.055
Missing 483 (38%) 487 (27%)
Continuous variables are given as mean ± standard error, and categorical
variables are presented as number (percentage). APACHE II, Acute Physiology
and Chronic Health Evaluation II; ASA, American Society of Anesthesiologists.
Heinrich et al. Critical Care 2014, 18:R150 Page 4 of 9
http://ccforum.com/content/18/4/R150(PCT) is not part of the standard blood testing but could
be chosen by the attending physician for early detection of
bacterial infection. The duration of mechanical ventilation
was measured from ICU admission until extubation. Me-
chanical ventilation hours were summarized in cases of
repetitive mechanical ventilation periods. SOFA score was
obtained only when patients stayed more than 24 hours in
the ICU.
Statistics
Statistical processing was performed by using SPSS® 20.0
(IBM, Armonk, NY, USA; significance level P <0.05).
Gaussian distribution of continuous variables was tested
by using the Kolmogorov-Smirnov test. If continuous
variables show Gaussian distribution, they are expressed
as mean value and standard error and were compared by
using the two-tailed Student t test. Categorical variables
are given as absolute number and percentage of occur-
rence. A univariate analysis of categorical variables was
performed by using the chi-squared test. Multivariate
analysis for categorical variables and Cox analysis for
survival variables was conducted where meaningful. An
ad posteriori sample size calculation with estimated mor-
tality rates of 3% and 5%, a statistical power of 0.8, and a
confidence interval of 95% revealed a required number of
at least 1,506 cases to enclose.
Results
The definitive analysis includes a total of 3,054 out of
3,212 available cases, indicating a dropout rate of 5%. A
group of 1,775 (58%) patients received etomidate ahead
of cardiac surgery to facilitate anesthesia induction and
endotracheal intubation. A group of 1,279 patients (42%)
did not receive etomidate. The underlying demographic
and preoperative data are shown in Table 1. There is a
significantly higher number of female patients in the
etomidate group: 554 (31%) versus 340 (27%) (P = 0.006).
All other preoperative and demographic items show no
significant difference.
Intraoperative data are shown in Table 2. The rate of
poor laryngoscopic view given as CML 3 or 4 in the
etomidate group is significantly lower than in the
non-etomidate group (4.5% versus 9.8%; P <0.001). The rate
of emergency cardiac surgery is significantly higher in the
etomidate group. All other intraoperative items show no
significant difference. A multivariate analysis revealed male
gender, the absence of etomidate, and high Mallampati
score as independent risk factors for poor laryngoscopic
view given as CML 3 or 4 (Table 3).
The main results addressing mortality and ICU course
are presented in Tables 4 and 5. ICU discharge rate at the
first postoperative day is significantly higher in the non-
etomidate group than in the etomidate group: 694 (56%)
versus 883 (51%) (P = 0.013). An isolated view on secondpostoperative day reveals significantly higher discharge
rate of the etomidate group: 297 (17%) versus 158 (13%)
(P <0.001). Summation of postoperative days 1 and 2
shows that there is no difference between the two study
groups: 852 (68%) versus 1,180 (68%) (P = 0.937). On sub-
sequent postoperative days, there was no difference be-
tween the groups until the end of observation on day 5.
APACHE score of more than 25 (hazard ratio (HR)
1.1; P <0.001), ASA score of 4 or 5 (HR 2.2; P <0.001),
ICU re-admission (HR 1.8; P = 0.004), requirement of






Number of patients 1,279 1,775
Priority of surgery
Elective 1,176 (92%) 1,562 (88%) <0.001
Emergency 103 (8%) 213 (12%)
Cormack-Lehane
1 681 (53%) 1,334 (75%) <0.001
2 466 (36%) 353 (20%) <0.001
3 114 (9%) 71 (4%) <0.001
4 12 (1%) 9 (0.5%) 0.154
Missing 4 (1%) 5 (0.5%) 0.875
Neuromuscular blocking
agent
Cisatracurium 1,204 (94%) 1,572 (89%) <0.001
Rocuronium 30 (2%) 182 (10%) <0.001
Suxamethonium 9 (1%) 21 (1%) 0.185
Missing 36 (3%) 0 (0%) <0.001
Cut-to-suture time, minutes 198.2 ± 1.7 202.2 ± 1.6 0.138
Bypass time, minutes 83.5 ± 1.0 87.1 ± 1.0 0.105
Aortic clamping, minutes 49.0 ± 0.7 51.6 ± 0.6 0.299
Mechanical ventilation, hours 19.69 ± 1.5 21.22 ± 1.3 0.355
Intraoperative epinephrine,
mg
102.0 ± 20.1 77.1 ± 14.2 0.054
Intraoperative norepinephrine,
mg
1,165.7 ± 108.8 1,178 ± 79.0 0.458
Continuous variables are given as mean ± standard error, and categorical
variables are presented as number (percentage).
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an ICU stay of longer than 3 days (HR 0.5; P = 0.001)
were identified as mortality-predicting variables in a
multivariate Cox regression analysis. For the adminis-
tration of etomidate, body mass index (BMI) of more than
40 kg/m2, age of more than 75 years, and gender Cox
analysis showed no significant influence on mortality
(Table 5).Table 3 Multivariate analysis to identify risk factors for
poor laryngoscopic view
Co-variable Odds ratio (95% CI) P value
Male gender 0.87 (0.48-1.25) <0.001
ASA score of 3 or 4 −0.12 (−0.93-0.69) 0.770
MLP 3 or 4 1.34 (1.04-1.64) <0.001
Emergency surgery 0.07 (−0.40-0.55) 0.760
Administration of etomidate −0.89 (−1.17-0.59) <0.001
Administration of rocuronium 0.04 (−0.59-0.67) 0.899
ASA, American Society of Anesthesiologists; CI, confidence interval; MLP,
Mallampati Score.Discussion
Key clinical outcome variables in patients with and with-
out etomidate-facilitated anesthesia induction ahead of
major cardiac surgery were comparable and showed no
statistically significant differences. The demographic and
preoperative data of our cohort indicate a good compar-
ability of the two study groups as there are no statistical
differences in age, BMI, APACHE II score, ASA status
distribution, and preoperative blood test results. The
higher frequency of female patients in the etomidate
group is statistically significant but clinically of limited
relevance. Little is known about gender differences in
postoperative outcome after major cardiac surgery. The
literature describes female gender as a risk factor for
poor outcome after cardiac surgery because women are
usually much older than male patients when undergoing
major cardiac surgery [28,29]. The statistically higher
rate of etomidate use in patients undergoing emergency
cardiac surgery is remarkable. This is most likely due to
the fact that emergency patients are more frequently in
unstable hemodynamic conditions and preoperative fas-
tening could not be awaited, so that a rapid sequence in-
duction demands a short-onset of the anesthetic drug.
The higher rate of emergency procedures in the etomi-
date group might also be causative for the slight in-
crease of preoperative CK in this group.
Multivariate analysis identified high Mallampati score
and male gender as risk factors for poor direct laryngos-
copy. Patients who received etomidate for anesthesia in-
duction showed significantly better intubation conditions
than patients with an alternative induction regime, which
is also reported by a former study [30]. Vasopressor re-
quirements, duration of surgery, and aortic clamping and
bypass times showed no significant difference between the
two study groups.
The hypothesis of this study was that anesthesia induc-
tion using etomidate might lead to poorer clinical out-
come due to impaired immune response. This comes
along with higher vulnerability for infections and consecu-
tively increased inflammatory serum parameters like CRP,
PCT, and leukocyte count. Statistical processing is focused
on relative differences between the study groups instead
of deviation from normal values in order to account for
the inherent inflammation associated with on-pump
cardiac surgery. A recently published study showed
that PCT is reliable in predicting severity of multi-
organ failure and outcome of systemic inflammatory
response [31]. In our study, none of the inflammation
blood parameters shows a significant difference be-
tween the etomidate and the non-etomidate groups in
the 5-day course we observed. To the best of our
knowledge, no former study has evaluated the effect of
etomidate on CRP, PCT, and leukocytes in cardiac surgery
patients before.
Table 4 Postoperative data of the two study groups
Categories Non-etomidate group Etomidate group P value
Number of patients 1,279 1,775
CRP, mg/L
Missing 140 (10.9%) 80 (4.5%)
Day 1 76.9 ± 1.2 77.0 ± 1.0 0.924
Day 2 183.8 ± 2.6 194.1 ± 2.2 0.382
Day 3 205.9 ± 3.8 211.5 ± 3.4 0.316
Day 4 189.7 ± 4.9 187.9 ± 4.3 0.340
Day 5 166.6 ± 6.5 150.9 ± 4.9 0.306
PCT, ng/mL
Missing 732 (57.2%) 963 (54.2%)
Day 1 4.1 ± 0.4 5.6 ± 0.5 0.053
Day 2 8.4 ± 0.9 10.0 ± 1.1 0.090
Day 3 7.9 ± 0.9 8.8 ± 0.9 0.312
Day 4 6.3 ± 0.9 6.6 ± 0.9 0.673
Day 5 4.7 ± 0.6 5.7 ± 0.7 0.254
Leukocytes, 103/μL
Missing 73 (5.7%) 63 (3.5%)
Day 1 12.8 ± 0.2 11.7 ± 0.1 0.061
Day 2 11.9 ± 0.2 11.7 ± 0.2 0.327
Day 3 11.9 ± 0.3 11.7 ± 0.3 0.899
Day 4 11.5 ± 0.4 11.3 ± 0.4 0.969
Day 5 11.7 ± 0.5 11.3 ± 0.4 0.776
CK
U/L 1347 ± 71 1642 ± 86 0.002
Missing 390 (30.5%) 226 (12.7%)
CK-MB
U/L 10.1 ± 0.2 10.0 ± 0.2 0.801
Missing 444 (34.7%) 292 (16.4%)
Troponin
μg/L 9.8 ± 0.6 11.5 ± 0.5 0.004
Missing 391 (30.5%) 230 (12.9%)
Hemodialysis
N 8.8% 10.2% 0.190
Hours 105 ± 12 112 ± 10 0.861
SOFA score
Missing 655 (51.2%) 884 (49.8%)
Day 1 7.9 ± 0.1 7.9 ± 0.1 0.340
Day 2 7.2 ± 0.2 7.3 ± 0.1 0.122
Day 3 7.4 ± 0.2 7.3 ± 0.2 0.697
Day 4 8.3 ± 0.3 8.2 ± 0.2 0.859
Day 5 8.8 ± 0.3 8.4 ± 0.3 0.394
Hospital days 17.4 ± 0.6 18.7 (0.6%) 0.250
ICU days 2.5 ± 0.1 2.6 ± 0.1 0.857
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Table 4 Postoperative data of the two study groups (Continued)
ICU discharge
Day 1 694 (56%) 883 (51%) 0.013
Day 2 158 (13%) (∑852; 68%) 297 (17%) (∑1180; 68%) 0.937
Day 3 151 (12%) (∑1003; 80%) 205 (12%) (∑1385; 80%) 0.795
Day 4 80 (6%) (∑1083; 87%) 115 (7%) (∑1500; 87%) 0.898
Day 5 39 (3%) (∑1122; 90%) 51 (3%) (∑1551; 90%) 0.776
ICU re-admission 70 (5.5%) 102 (5.8%) 0.746
7-day mortality 39 (3.0%) 64 (3.6%) 0.401
30-day mortality 66 (5.2%) 106 (6.0%) 0.337
Overall in hospital mortality 82 (6.4%) 121(6.8) 0.657
Continuous variables are given as mean ± standard error, and categorical variables are presented as number (percentage). CK, creatinkinasis; CML, Cormack and
Lehane; CRP, C-reactive protein; ICU, intensive care unit; PCT, procalcitonine; SOFA, Sequential Organ Failure Assessment.
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score to reflect multi-organ failure, severity, and outcome
in patients with sepsis [24,32,33]. In the present dataset,
this score was documented when patients stayed longer
than 24 hours in the ICU. We observed the SOFA score
for five consecutive days and found no significant differ-
ence on any day between the etomidate and the non-
etomidate groups. Renal dysfunction and failure constitute
one of the most common organ dysfunctions in patients
with sepsis [34,35] and are also associated with major
cardiac surgery [36]. In the present study, we analyzed the
rate of patients requiring renal replacement therapy as well
as the hemodialysis hours per patient with renal failure.
Neither the rate of patients needing hemodialysis nor the
duration of hemodialysis (if required) showed statistically
different results in the etomidate and the non-etomidate
group. If etomidate administration for anesthesia induction
ahead of cardiac surgery would have impaired the clinical
outcome, mechanical ventilation hours should also be
increased in this group. However, we found no evidence
that single-dose use of etomidate ahead of major cardiac
surgery increases the duration of mechanical ventilation.
Our results are in line with a comparable analysis by
Wagner and colleagues in which a prolonged mechan-
ical ventilation time after administration of etomidate inTable 5 Multivariate cox analysis with survival data
Co-variables
Administration of etomidate
Body mass index of more than 40 kg/m2
Age of more than 75 years
ASA score of 4 or 5
APACHE II score of more than 25
ICU stay of more than 3 days
Re-admission to the ICU
Renal failure, hemofiltration within ICU stay
APACHE II, Acute Physiology and Chronic Health Evaluation II; ASA, American Societpatients undergoing coronary bypass surgery was not
reported [21]. Additionally, a single dose of etomidate
in patients with sepsis did not lead to an increased
mechanical ventilation time [13]. In summary, we found
no evidence that a single dose of etomidate for induc-
tion of anesthesia increased the risk of postoperative
mortality or morbidity.
In patients who already have sepsis, the discussion of
whether single-dose etomidate increases mortality risk
is controversial. Some retrospective analyses suggested
an increased risk of mortality in septic patients who
received etomidate for intubation [5,6,9,32]. In contrast
to these reports, other studies deny an increased risk of
mortality for septic patients who received etomidate
[10,12-16]. It could be hypothesized that cardiac surgery
patients with severe comorbidities and impaired ven-
tricular function should more likely have etomidate-
triggered adrenal insufficiency and consecutive poor
outcome. However, in our cohort, we found no evidence
that etomidate leads to increased early or late ICU mor-
tality. Even the total in-hospital mortality showed no
difference. Moreover, neither the total length of stay in
the ICU nor the total hospital stay differs significantly
between the etomidate and the non-etomidate group.









y of Anesthesiologists; CI, confidence interval; ICU, intensive care unit.
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ever, on day 2, the discharge rate is already balanced and
remains balanced until the end of observation on day 5.
The higher rate of emergency interventions in the etomi-
date group might be causative for a lower discharge rate
on postoperative day 1. This theory is supported by the
significantly higher peak of CK in the etomidate group
which might be higher after myocardial infarction and
emergency cardiac surgery. In regard to re-admission to
the ICU, our study found no evidence that etomidate
given ahead of cardiac surgery leads to a higher ICU
re-admission rate. Given all of the postoperative items,
the etomidate group showed no statistically significant or
clinically relevant poorer outcome in any of the observed
variables.
However, our study has some limitations which are
based mainly on the retrospective design of the analysis.
Owing to missing data in the pre- and postoperative
serum test results, these items could not be taken into
account for the Cox analysis. The SOFA and APACHE
II scores show missing data and were not taken into
account for the Cox analysis. The SOFA score was doc-
umented only for patients with more than 24 hours in
the ICU. Cases which were discharged in the morning
after surgery lack of SOFA score. APACHE II score was
obtained when preoperative data were available. Where
patients were transferred from external wards, these
datasets were not available and APACHE II score could
not be obtained.
Owing to its retrospective character, the study lacks a
randomization protocol. Although the selection of induc-
tion regime with or without etomidate was based on the
personal preferences of the attending anesthesiologist, a
high number of anesthesiologists (135) performing the
anesthesia procedures of the study might preclude a selec-
tion bias.Conclusions
This study found no evidence for differences in key clin-
ical outcome parameters based on anesthesia induction
with or without administration of a single dose of eto-
midate. This holds particularly true for mortality, length
of hospital stay, length of ICU stay, re-admission to the
ICU, duration of mechanical ventilation, postoperative
systemic inflammatory response or sepsis discriminated
by inflammatory parameters, renal failure, or SOFA score.
Moreover, multivariate analysis revealed better intubation
conditions in the etomidate group. Despite the known and
undisputable risk of adrenal suppression and taking the
beneficial effects for hemodynamic unstable and cardiac
impaired patients into account, etomidate should remain
an acceptable option in clinical routine for anesthesia
induction.Key messages
Single-dose etomidate ahead of major on-pump cardiac
surgery
 is not associated with higher postoperative
mortality.
 is not associated with an increased rate of
postoperative infection discriminated by serum tests
and morbidity scores.
 is not associated with a higher SOFA score or an
increased rate of renal replacement therapy.
 does not change length of ICU or total hospital stay.
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